title: Rapid identification of neuraminidase inhibitor resistance mutations in seasonal influenza virus A(H1N1), A(H1N1)2009, and A(H3N2) subtypes by melting point analysis.
abstract: The high mutation rate of influenza virus, combined with the increasing worldwide use of influenza virus-specific drugs, allows the selection of viruses that are resistant to the currently available antiviral medications. Therefore, reliable tests for the rapid detection of drug-resistant influenza virus strains are required. We evaluated the use of a procedure involving real-time polymerase chain reaction (PCR) followed by melting point analysis (MPA) of hybrids formed between the PCR product and a specific oligonucleotide probe for the identification of point mutations in the influenza A virus neuraminidase gene (NA) that are associated with oseltamivir resistance [resulting in the amino acid change H275Y for seasonal and pandemic influenza A(H1N1) viruses and E119V for A(H3N2) viruses]. Therefore, 54 seasonal A(H1N1) (12 oseltamivir-resistant and 42 sensitive strains), 222 A(H1N1)2009 (5 resistant, 217 sensitive), and 51 A(H3N2) viruses (2 resistant, 49 sensitive) were tested by MPA, and the results were compared to those obtained by sequencing the NA gene. The results clearly indicate that the identification of drug resistance mutations by MPA is as accurate as sequencing, irrespective of whether MPA is performed using clinical material or the corresponding isolate. MPA enables a clear identification of mutations associated with antiviral resistance.
authors.affiliation: Department of Virology, Medical University Vienna, Kinderspitalgasse 15, 1095, Vienna, Austria.
authors.forename: M
authors.initials: M
authors.lastname: Redlberger-Fritz
authors.forename: S W
authors.initials: SW
authors.lastname: Aberle
authors.forename: R
authors.initials: R
authors.lastname: Strassl
authors.forename: T
authors.initials: T
authors.lastname: Popow-Kraupp
mesh_terms: D000998:Antiviral Agents / Q000494:pharmacology*; D024882:Drug Resistance, Viral; D005838:Genotype; D006801:Humans; D053118:Influenza A Virus, H1N1 Subtype / Q000187:drug effects / Q000235:genetics*; D053122:Influenza A Virus, H3N2 Subtype / Q000187:drug effects / Q000235:genetics*; D020125:Mutation, Missense; D009439:Neuraminidase / Q000235:genetics*; D012367:RNA, Viral / Q000235:genetics; D044366:Transition Temperature; D014764:Viral Proteins / Q000235:genetics*; D014773:Virology / Q000379:methods*
chemical_list: D000998:Antiviral Agents; D012367:RNA, Viral; D014764:Viral Proteins; C487630:NA protein, influenza A virus; D009439:Neuraminidase
references.citation: Antimicrob Agents Chemother. 2006 Jul;50(7):2395-402
references.pmid: 16801417
references.citation: J Virol Methods. 2008 Nov;153(2):257-62
references.pmid: 18718489
references.citation: J Clin Virol. 2010 Dec;49(4):277-82
references.pmid: 20846903
references.citation: J Virol Methods. 2009 Jun;158(1-2):190-4
references.pmid: 19428589
references.citation: Vaccine. 2007 Aug 10;25(32):6061-9
references.pmid: 17601639
references.citation: JAMA. 2007 Apr 4;297(13):1435-42
references.pmid: 17405969
references.citation: Emerg Infect Dis. 2009 Feb;15(2):155-62
references.pmid: 19193257
references.citation: Virus Res. 2004 Jul;103(1-2):199-203
references.pmid: 15163510
references.citation: J Infect. 2007 Sep;55(3):267-72
references.pmid: 17604839
references.citation: Rev Med Virol. 2000 Jan-Feb;10(1):45-55
references.pmid: 10654004
references.citation: Clin Infect Dis. 2009 Feb 15;48(4):389-96
references.pmid: 19133796
references.citation: J Virol Methods. 2008 Nov;153(2):134-41
references.pmid: 18725246
references.citation: Respirology. 2008 Nov;13(7):950-71
references.pmid: 18922142
references.citation: J Clin Virol. 2010 Jan;47(1):34-7
references.pmid: 19857993
references.citation: N Engl J Med. 2000 Jan 27;342(4):232-9
references.pmid: 10648764
references.citation: Pediatr Infect Dis J. 1997 Nov;16(11):1065-8
references.pmid: 9384341
references.citation: Am J Public Health. 1993 Dec;83(12):1712-6
references.pmid: 8259800
references.citation: Antiviral Res. 2009 Apr;82(1):29-33
references.pmid: 19428592
references.citation: J Clin Microbiol. 2010 Oct;48(10):3517-24
references.pmid: 20668122
references.citation: J Virol Methods. 2011 May;173(2):259-65
references.pmid: 21349290
references.citation: Antimicrob Agents Chemother. 2008 Sep;52(9):3284-92
references.pmid: 18625765
references.citation: J Clin Microbiol. 2006 Dec;44(12):4541-4
references.pmid: 17035493
references.citation: J Clin Microbiol. 2004 Apr;42(4):1564-9
references.pmid: 15071005
references.citation: N Engl J Med. 2002 Dec 26;347(26):2097-103
references.pmid: 12501221
references.citation: Lancet. 2004 Aug 28-Sep 3;364(9436):759-65
references.pmid: 15337401
references.citation: J Infect Dis. 2001 Feb 15;183(4):523-31
references.pmid: 11170976
references.citation: J Clin Microbiol. 2003 Feb;41(2):742-50
references.pmid: 12574276